---
title: "Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | SVRA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287062772.md"
description: "Savara presented new biomarker data from the IMPALA-2 Phase 3 clinical trial of Molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS International Conference 2026."
datetime: "2026-05-20T04:15:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287062772.md)
  - [en](https://longbridge.com/en/news/287062772.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287062772.md)
generator: "portal-rs"
---

# Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | SVRA Stock News

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | SVRA Stock News

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVI](https://longbridge.com/en/news/295577813.md)
- [SVRA: MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market](https://longbridge.com/en/news/295577539.md)
- [Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI program](https://longbridge.com/en/news/292798258.md)
- [Savara Q2 loss widens as operating expenses rise](https://longbridge.com/en/news/295574578.md)
- [Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 million](https://longbridge.com/en/news/290489697.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**